or Try an Advanced Search...

    Technical Analysis for XLO - Xilio Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 0.92 -2.61% -0.02
    XLO closed down 7.73 percent on Wednesday, November 20, 2024, on approximately normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Flat Down
    Historical XLO trend table...
    Date Alert Name Type % Chg
    200 DMA Support Bullish -2.61%
    Wide Bands Range Expansion -2.61%
    NR7 Range Contraction -10.14%
    Narrow Range Bar Range Contraction -10.14%
    Inside Day Range Contraction -10.14%
    Wide Bands Range Expansion -10.14%
    Gapped Up Strength -10.14%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.73%
    Inside Day Range Contraction -5.73%
    Wide Bands Range Expansion -5.73%
    Older End-of-Day Signals for XLO ...

       Recent Intraday Alerts

    Alert Time
    2x Volume Pace about 3 hours ago
    60 Minute Opening Range Breakdown about 3 hours ago
    1.5x Volume Pace about 3 hours ago
    50 DMA Support about 4 hours ago
    Down 5% about 4 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    XLO Chart by TradingView
    Basic chart:

    Profile

    Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune system for cancer patients. Its checkpoint inhibitor programs include XTX101, is a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1 clinical trials in patients with solid tumors; and cytokine programs comprise XTX202, XTX301, and XTX401, which are modified form of IL-2 that is masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Tumor Cancer Immunotherapy Immunotherapies Immune Checkpoint Checkpoint Inhibitor Tumor Microenvironment

    Is XLO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 8 Xilio Therapeutics reports Q3 results
    Nov 7 Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
    Nov 7 Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
    Oct 30 Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    Oct 4 Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    Oct 2 Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Aug 28 Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
    Aug 8 Xilio Therapeutics GAAP EPS of -$0.24, revenue of $2.4M
    Aug 8 Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
    Jun 29 Can Xilio Therapeutics (NASDAQ:XLO) Afford To Invest In Growth?
    See more XLO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.93
    52 Week Low 0.49
    Average Volume 272,020
    200-Day Moving Average 0.93
    50-Day Moving Average 0.91
    20-Day Moving Average 1.10
    10-Day Moving Average 1.01
    Average True Range 0.14
    RSI (14) 46.24
    ADX 25.43
    +DI 18.47
    -DI 24.54
    Chandelier Exit (Long, 3 ATRs) 1.12
    Chandelier Exit (Short, 3 ATRs) 1.20
    Upper Bollinger Bands 1.42
    Lower Bollinger Band 0.78
    Percent B (%b) 0.25
    BandWidth 58.25
    MACD Line 0.02
    MACD Signal Line 0.05
    MACD Histogram -0.0333
    Fundamentals Value
    Market Cap 25.91 Million
    Num Shares 27.5 Million
    EPS -2.96
    Price-to-Earnings (P/E) Ratio -0.32
    Price-to-Sales 0.00
    Price-to-Book 0.31
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.05
    Resistance 3 (R3) 1.06 1.03 1.03
    Resistance 2 (R2) 1.03 1.00 1.03 1.03
    Resistance 1 (R1) 0.99 0.98 0.97 0.98 1.02
    Pivot Point 0.96 0.96 0.95 0.95 0.96
    Support 1 (S1) 0.91 0.93 0.90 0.90 0.86
    Support 2 (S2) 0.88 0.91 0.88 0.85
    Support 3 (S3) 0.84 0.88 0.85
    Support 4 (S4) 0.83